Clinical trials in Groningen – page 41

557 clinical trials in Groningen, The Netherlands across 8 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in the NetherlandsKlinischOnderzoek.nl

Groningen at a glance

557

clinical trials

Research sites8

Quick filters

557 trials in Groningen

Open in trial search

Plasma cell myeloma refractory

Not recruiting

Registered drugNo placebo

Study Comparing Teclistamab with Pomalidomide, Bortezomib, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma After 1-3 Prior Treatments

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Janssen Cilag International

Contact Research Centre

IgA nephropathy

Not recruiting

Registered drug

Study on Ravulizumab for Adults with Immunoglobulin A Nephropathy (IgAN) to Preserve Kidney Function

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Ravulizumab
Sponsor:Alexion Pharmaceuticals Inc.

Contact Research Centre

Chronic lymphocytic leukaemia

Not recruiting

Registered drugNo placebo

Study of ibrutinib and venetoclax combination therapy for patients with relapsed or refractory chronic lymphocytic leukemia who have adequate kidney function

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Ibrutinib
Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Contact Research Centre

Malignant melanoma stage III

Not recruiting

Registered drug

Study on Pembrolizumab for Patients with High-Risk Stage III Melanoma After Surgery

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

HER2 mutant non-small cell lung cancer

Not recruiting

Registered drugNo placebo

Study on Trastuzumab Deruxtecan for Patients with Advanced Non-Small Cell Lung Cancer with HER2 Mutations

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Bladder cancer

Not recruiting

Registered drugNo placebo

Study on Durvalumab, Tremelimumab, and Enfortumab Vedotin for Patients with Muscle Invasive Bladder Cancer Ineligible or Refusing Cisplatin

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Durvalumab
Sponsor:AstraZeneca AB

Contact Research Centre

Diffuse large B-cell lymphoma+2

Not recruiting

Registered drug

Study on Golcadomide and R-CHOP Drug Combination for Patients with Untreated High-risk Large B-cell Lymphoma

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Celgene Corp.

Contact Research Centre

Study of Tepotinib for Patients with Advanced Lung Cancer with MET Exon 14 Skipping Alterations or MET Amplification

Not recruiting

InvestigationalNo placebo

Study of Tepotinib for Patients with Advanced Lung Cancer with MET Exon 14 Skipping Alterations or MET Amplification

InvestigationalNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Tepotinib
Sponsor:Merck Healthcare KGaA

Contact Research Centre

Plasma cell myeloma refractory

Not recruiting

Registered drugNo placebo

Study Comparing Teclistamab with Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Bortezomib
Sponsor:Janssen Cilag International

Contact Research Centre

Chronic lymphocytic leukaemia

Not recruiting

Registered drugNo placebo

Study Comparing Ibrutinib, Venetoclax, and Obinutuzumab for Untreated Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo

The Netherlands

Participants:18–64 years · 65+ years
Substances:Ibrutinib
Sponsor:University Of Cologne

Contact Research Centre

Atrial fibrillation+2

Not recruiting

Registered drug

Study on Asundexian and Apixaban for Preventing Stroke in Adults with Atrial Fibrillation at Risk for Stroke

Registered drug

The Netherlands

Participants:18–64 years · 65+ years
Substances:Apixaban
Sponsor:Bayer AG

Contact Research Centre

Dermatitis atopic

Not recruiting

Registered drug

Study of Upadacitinib and Topical Corticosteroids for Adolescents and Adults with Moderate to Severe Eczema

Registered drug

The Netherlands

Participants:0–17 years · 18–64 years · 65+ years
Substances:Hydrocortisone
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Other cities in the Netherlands

The busiest research cities in the country

All 103 cities in the Netherlands

Clinical research in Groningen

What the registry says about research in the country

01 Cardiovascular Research

Advanced studies focusing on heart disease and cardiovascular conditions, including innovative treatments for ATTR amyloidosis and prevention strategies for heart failure.

Cardiomyopathy Treatments
Heart Failure Prevention
Peripheral Arterial Disease

Multiple trials exploring novel therapeutic approaches and preventive measures for various cardiac conditions.

02 Oncology Studies

Comprehensive research into various cancer types, including melanoma and lung cancer, with particular focus on innovative treatment approaches and metastatic disease management.

Advanced Breast Cancer
Small Cell Lung Cancer
Brain Metastases

Investigation of targeted therapies and combination treatments for improved patient outcomes.

03 Metabolic Disorders

Clinical investigations focusing on obesity and type 2 diabetes, testing new therapeutic approaches for weight management and metabolic control.

Weight Management
Diabetes Treatment
Metabolic Health

Evaluation of novel medications combined with lifestyle interventions for optimal patient care.

Back to the Netherlands All countries